Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132301) titled 'A Dual-Center, Prospective, Exploratory Study of Vunakizumab, an IL-17A Inhibitor, for the Treatment of Acne Fulminans' on Sept. 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Huashan Hospital, Fudan University
Condition:
Acne fulminans (AF) i
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-09-11
Target Sample Size: Experimental Group:32;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=342968
Disclaimer: Curated by HT Syndication....